Skip to main content

Table 1 Comparison of the groups with regard to histological, biochemical, and radiological study assessments

From: Epidermal growth factor or platelet-rich plasma combined with induced membrane technique in the treatment of segmental femur defects: an experimental study

  Group 1 (PRP) Group 2 (EGF) Group 3 (controls) p
Assessments at week 6 (mean ± SD)
 Histological CD31 assessment (counts/mm2) 143.7 ± 8.2 151.1 ± 9.2 125.2 ± 13.3 < 0.001
 Membrane TGF level (ng/mL) 246.4 ± 54.3 257.7 ± 55.2 141.8 ± 20.8 < 0.001
 Membrane VEGF level (pg/mL) 842.0 ± 98.5 754.8 ± 118.7 430.5 ± 92.2 < 0.001
Assessments at week 12 (mean ± SD)
 Histological CD31 assessment (counts/mm2) 137.3 ± 17.3 138.1 ± 14.0 99.6 ± 25.5 0.003
 Membrane TGF level (ng/mL) 397.4 ± 44.4 379.3 ± 63.3 326.4 ± 42.0 0.032
 Membrane VEGF level (pg/mL) 318.0 ± 95.2 273.0 ± 72.1 228.9 ± 44.9 0.086
 Bone VEGF level (pg/mL) 192.2 ± 6.7 198.1 ± 5.7 176.3 ± 7.2 0.003
 Bone BMP-2 level (pg/mL) 191.9 ± 8.4 237.6 ± 37.3 117.1 ± 43.0 0.012
Lane score (median, range)     
 Anteroposterior 4 (3-4) 3 (2-4) 1 (1-2) 0.015
 Lateral 4 (2-4) 3.5 (2-4) 1 (1-2) 0.026
 CT 3 (2-4) 3 (2-3) 1 (1-2) 0.026
 3D 3.5 (2-4) 4 (3-4) 1.5 (1-3) 0.044
  1. Abbreviations: PRP platelet rich plasma, EGF epidermal growth factor, CD 31 cluster of differentiation 31, TGF-beta transforming growth factor-beta, BPM-2 bone morphogenetic protein 2, VEGF vascular endothelial growth factor, CT computed tomography, 3D three-dimensional